Aflibercept Package Insert

Additional Coding Edits - Connecticare Inc
(J0178) Aflibercept is payable when billed with diagnoses specific to FDA approved indications including central retinal vein occlusion, with a diagnosis of retinal edema. Dosage is limited based on FDA package insert. Age restrictions apply to less than 18 years old. Unilateral or bilateral modifiers are required. Must be billed with ... Read Here

Last Review Status/Date - FEP Blue
Eylea (aflibercept) and Macugen (pegaptanib) are vascular endothelial growth factor (VEGF) inhibitors used to treat patients with wet (neovascular) age-related macular degeneration (AMD). ... Return Doc

Aflibercept ELISA Assay Kit - Eagle Biosciences
Aflibercept has broad affinity for all ligands that bind to these receptors, including the valid version of the package insert provided with the kit. Be sure that Aflibercept ELISA Assay Kit 9/12 1 2 ... Read Document

Clinical Evidence In Support Of Ziv-aflibercept In ...
Aflibercept and FOLFIRI in patients with metastatic colorectal cancer after failure of an oxaliplatin regimen. Presented at: 48th Annual American Society of Clinical Oncology Meeting, Chicago, IL, USA, June 1-5, 2012. Abstract 3505. 7. ... Read Content

OPHTHALMIC VEGF INHIBITORS Eylea (aflibercept), Macugen ...
OPHTHALMIC VEGF INHIBITORS Eylea (aflibercept), Macugen (pegaptanib) VEGF Inhibitors FEP Clinical Rationale edema following RVO, DR and DME. Patients taking VEGF inhibitors must be monitored and managed for intravitreal injection procedure associated effects, elevated intraocular pressure and appropriate perfusion of the optic nerve head. ... Doc Retrieval

Baricitinib - Wikipedia
Baricitinib (trade name Olumiant) is a drug for the treatment of rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved in Europe. ... Read Article

MEDICAL POLICY STATEMENT - CareSource
Aflibercept acts as a soluble decoy receptor that binds VEGF and Refer to the product package insert for dosing, administration and safety guidelines. The Medical Policy Statement detailed above has received due consideration as defined ... Fetch This Document

L36962: Medicare Part A/B Local Coverage Determination (LCD ...
The package insert or generally accepted by peers and the reason for additional services is not justified by documentation. Dose and frequency should be in accordance with the FDA label or recognized compendia (for off-label uses). ... Fetch Doc

ZALTRAP (ziv-aflibercept)
Aflibercept), combined with 5-fluorouracil, leucovorin, and irinotecan is approved for treatment of metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin- containing regimen (1). ... Document Viewer

These Results Are Supplied For Informational Purposes Only.
According to template: QSD-001970 VERSION N° 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. ... Get Document

Barry White - Irish Haemophilia Society
What is rFIXFc? •rFIXFc is a recombinant fusion protein, composed of recombinant factor IX covalently fused to the Fc domain of human immunoglobulin G1 (IgG1).1,2 •rFIXFc was developed to extend the half-life of factor IX, in order to achieve prolonged haemostatic protection in patients with haemophilia B ... Read Here

Annals Of Pharmacotherapy Ziv-aflibercept (Zaltrap) For The ...
Ziv-aflibercept and colorectal cancer. Additional references were identified from the reference lists of the articles identi-fied. Guidelines from the National Comprehensive Cancer Network were reviewed as well as the Zaltrap package insert from Regeneron Pharmaceuticals, Inc. Pharmacology Angiogenesis, the formation and differentiation of the vas- ... Fetch Here

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
1 ml solution for injection contains 4 0 mg aflibercept*. One pre-filled syringe contains 90 microlitres, equivalent to 3.6 mg aflibercept. This provides a usable amount to deliver a single dose of 50 microlitres containing 2 mg aflibercept. ... Read More

Local Coverage Article For Ranibizumab (e.g., Lucentis ) And ...
And/or frequency are different from the FDA approved package insert, literature support for the specific schedule chosen should be available. Coding Information: The administration for ranibizumab or aflibercept must be billed on the same claim as the drug, with CPT code 67028 (intravitreal injection of a pharmacologic agent). ... Get Doc

Study Of COmparative Treatments For REtinal Vein Occlusion 2 ...
Aflibercept every 4 weeks. Short title: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) VERSION 4.0 October 12, 2016 Appendix 4: Dexamethasone Package Insert..65 Note: A separate SCORE2 Manual of Policies and Procedures (MOPP ... Access Doc

Lestaurtinib - Wikipedia
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. ... Read Article

ZALTRAP - Baptist Health Plan
Adults: 4 mg/kg IV over 1 hour on day 1 every 2 weeks in combination with FOLFIRI regimen until disease progression or unacceptable toxicity. Administer ziv-aflibercept prior to FOLFIRI. ... Return Document

EYLEA (aflibercept Intravitreal Injection)
Prior Authorization DRUG Guidelines Last Eylea™ injection [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; November, 2011. 2. Data on file. 23. Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet ... Visit Document

5.21.25 Zaltrap Ziv-aflibercept 3 18 16 EA
Zaltrap (ziv-aflibercept) Background Zaltrap (ziv-aflibercept) is a recombinant fusion protein consisting of Vascular Endothelial Growth Zaltrap [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; September 2014 Policy History Date Action October 2012 New policy. ... Get Doc

WHO Pharmaceuticals NEWSLETTER 2
That the package insert of aflibercept (Zaltrap®) will be updated to include the new information related to the risk of osteonecrosis of the jaw (ONJ). In addition, in agreement with the NPRA, the product registration holder of aflibercept has issued a Direct Health-care Professional Communication (DHPC) letter on this matter. ... Retrieve Content

SCHEDULING STATUS: S4 - Bayer.co.za
Aflibercept does not accumulate in the plasma when administered intravitreally every 4 weeks. It is estimated that after intravitreal administration of 2 mg to patients, the mean maximum plasma concentration of free aflibercept is more than a 100 fold lower than the concentration of aflibercept required to half-maximally bind systemic VEGF. ... Retrieve Document